CHMP backs Bayer’s tumour-agnostic drug Vitrakvi – PMLiVE

CHMP backs Bayer’s tumour-agnostic drug Vitrakvi – PMLiVE
CHMP backs Bayer's tumour-agnostic drug Vitrakvi  PMLiVEBayer's Vitrakvi has become the first drug in Europe recommended to treat cancer based on a molecular signature, rather than where it originated in the body. ... read more
Source: Google NewsPublished on 2019-07-29